Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer
Atezolizumab was the first immune checkpoint inhibitor (ICI) to be introduced as a first‐line treatment option for extensive‐stage small cell lung cancer (ES‐SCLC), in combination with carboplatin and etoposide (CE) chemotherapy. However, SCLC treatment options after progression to first‐line chemot...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Wiley
2020-09-01
|
| Colección: | Thoracic Cancer |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1111/1759-7714.13588 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|